Combination of | |
---|---|
Medetomidine | alpha2-adrenoceptor agonist |
Vatinoxan | alpha2-adrenoceptor antagonist |
Clinical data | |
Trade names | Zenalpha |
License data | |
Routes of administration | Intramuscular |
ATC code |
|
Legal status | |
Legal status |
Medetomidine/vatinoxan, sold under the brand name Zenalpha, is a veterinary fixed dose combination medication used as a sedative and analgesic for dogs. [1] [2] It contains medetomidine, an alpha2-adrenoceptor agonist, as the hydrochloride; and vatinoxan, an alpha2-adrenoceptor antagonist, as the hydrochloride. [2] [3]
It was approved for veterinary use in the United States in May 2022, [2] and in Canada in May 2023. [1]